A Randomized Controlled Open-label Single-center Study to Assess the Efficacy of TCZ in Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Latest Information Update: 12 Apr 2024
Price :
$35 *
At a glance
- Drugs Tocilizumab (Primary) ; Prednisolone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms InterCept
- 22 Mar 2024 Trial design, published in the Trials
- 07 Nov 2023 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.
- 07 Nov 2023 Planned primary completion date changed from 1 Oct 2025 to 1 Oct 2026.